Thanks to Karen Veverka for forwarding the following information:
This message contains search results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).
-
Xanthones from the Botanical Dietary Supplement Mangosteen (Garcinia mangostana) with Aromatase Inhibitory Activity.
Twelve xanthone constituents of the botanical dietary supplement mangosteen (the pericarp of Garcinia mangostana) were screened using a noncellular, enzyme-based microsomal aromatase inhibition assay. Of these compounds, garcinone D ( 3), garcinone E ( 5), alpha-mangostin ( 8), and gamma-mangostin ( 9) exhibited dose-dependent inhibitory activity. In a follow-up cell-based assay using SK-BR-3 breast cancer cells that express high levels of aromatase, the most potent of these four xanthones was gamma-mangostin ( 9). Because xanthones may be consumed in substantial amounts from commercially available mangosteen products, the consequences of frequent intake of mangosteen botanical dietary supplements require further investigation to determine their possible role in breast cancer chemoprevention.
PMID: 18558747 [PubMed - as supplied by publisher]
-
Related Articles
- Antioxidant xanthones from the pericarp of Garcinia mangostana (Mangosteen). [J Agric Food Chem. 2006]
- Inhibition of cyclooxygenase and prostaglandin E2 synthesis by gamma-mangostin, a xanthone derivative in mangosteen, in C6 rat glioma cells. [Biochem Pharmacol. 2002]
- Xanthones with quinone reductase-inducing activity from the fruits of Garcinia mangostana (Mangosteen). [Phytochemistry. 2008]
- Inhibitory effect of xanthones isolated from the pericarp of Garcinia mangostana L. on rat basophilic leukemia RBL-2H3 cell degranulation. [Bioorg Med Chem. 2008]
- Garcinia mangostana: a source of potential anti-cancer lead compounds against CEM-SS cell line. [J Asian Nat Prod Res. 2008]
- » See all Related Articles...
-
Related Reviews
- The potential of aromatase inhibitors in breast cancer prevention. [Endocr Relat Cancer. 1999]
No comments:
Post a Comment